Associated Papers
PanDrugs2: prioritizing cancer therapies using integrated individual multi-omics data.
Jiménez-Santos MJ et al.
Nucleic Acids Research, 2023
Decoding molecular programs in melanoma brain metastases.
Radke J et al.
Nature Communications, 2022
36435874 (PubMed )
Supplement: 41467_2022_34899_MOESM18_ESM.xlsx › Figure_4d__left
Detection of oncogenic and clinically actionable mutations in cancer genomes critically depends on variant calling tools.
Garcia-Prieto CA et al.
Bioinformatics (oxford, England), 2022
35512388 (PubMed )
Supplement: btac306_supplementary_data.zip › Supplementary_files.zip › Supplementary_files › Supplementary_file_7.xlsx › Sheet1
Spectrum of BRAF Aberrations and Its Potential Clinical Implications: Insights From Integrative Pan-Cancer Analysis.
Yi Q et al.
Frontiers in Bioengineering and Biotechnology, 2022
35910024 (PubMed )
Supplement: Table2.XLSX › table
Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden.
Georgoulias G et al.
Frontiers in Immunology, 2022
36389735 (PubMed )
Supplement: Table_7.xlsx › BRAF
BRN2 is a non-canonical melanoma tumor-suppressor.
Hamm M et al.
Nature Communications, 2021
34140478 (PubMed )
Supplement: 41467_2021_23973_MOESM9_ESM.xlsx › Figure_1E
Integrated molecular drivers coordinate biological and clinical states in melanoma.
Conway JR et al.
Nature Genetics, 2020
33230298 (PubMed )
Supplement: NIHMS1637640-supplement-SuppData4.xlsx › ScarHRD_output
NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics.
Cirenajwis H et al.
Molecular Oncology, 2017
28267273 (PubMed )
Supplement: MOL2-11-438-s002.xls › SupplementaryTable2.txt
Select a paper to view details